Global β Adrenoceptor Agonists Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 β Adrenoceptor Agonists Market Overview

• 1.1 Product Overview and Scope of β Adrenoceptor Agonists
• 1.2 Classification of β Adrenoceptor Agonists by Types
  • 1.2.1 Global β Adrenoceptor Agonists Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global β Adrenoceptor Agonists Revenue Market Share by Types in 2018
  • 1.2.3 Isoprenaline
  • 1.2.4 Dobutamine
  • 1.2.5 Salbutamol
  • 1.2.6 Terbutaline
  • 1.2.7 Salmeterol
  • 1.2.8 Formoterol
  • 1.2.9 Pirbuterol
• 1.3 Global β Adrenoceptor Agonists Market by Application
  • 1.3.1 Global β Adrenoceptor Agonists Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Chronic Heart Failure
  • 1.3.3 Myocardial Infarction
  • 1.3.4 Postoperative Hypotension
  • 1.3.5 Bronchial Asthma
  • 1.3.6 Asthmatic Bronchitis
  • 1.3.7 Emphysema
  • 1.3.8 Others
• 1.4 Global β Adrenoceptor Agonists Market by Regions
  • 1.4.1 Global β Adrenoceptor Agonists Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) β Adrenoceptor Agonists Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) β Adrenoceptor Agonists Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) β Adrenoceptor Agonists Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) β Adrenoceptor Agonists Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) β Adrenoceptor Agonists Status and Prospect (2014-2024)
• 1.5 Global Market Size of β Adrenoceptor Agonists (2014-2024)

2 Manufacturers Profiles

• 2.1 Ivax Pharmaceuticals
  • 2.1.1 Business Overview
  • 2.1.2 β Adrenoceptor Agonists Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Ivax Pharmaceuticals β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Physicians Total Care
  • 2.2.1 Business Overview
  • 2.2.2 β Adrenoceptor Agonists Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Physicians Total Care β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 Baxter Healthcare
  • 2.3.1 Business Overview
  • 2.3.2 β Adrenoceptor Agonists Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 Baxter Healthcare β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Sanofi
  • 2.4.1 Business Overview
  • 2.4.2 β Adrenoceptor Agonists Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Sanofi β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Pfizer
  • 2.5.1 Business Overview
  • 2.5.2 β Adrenoceptor Agonists Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Pfizer β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Bedford Laboratories
  • 2.6.1 Business Overview
  • 2.6.2 β Adrenoceptor Agonists Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Bedford Laboratories β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Novartis
  • 2.7.1 Business Overview
  • 2.7.2 β Adrenoceptor Agonists Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Novartis β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Sterimax
  • 2.8.1 Business Overview
  • 2.8.2 β Adrenoceptor Agonists Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Sterimax β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Teligent
  • 2.9.1 Business Overview
  • 2.9.2 β Adrenoceptor Agonists Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Teligent β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 AstraZeneca
  • 2.10.1 Business Overview
  • 2.10.2 β Adrenoceptor Agonists Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 AstraZeneca β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Hikma Pharmaceuticals
  • 2.11.1 Business Overview
  • 2.11.2 β Adrenoceptor Agonists Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Hikma Pharmaceuticals β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Av Kare
  • 2.12.1 Business Overview
  • 2.12.2 β Adrenoceptor Agonists Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Av Kare β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Impax Laboratories
  • 2.13.1 Business Overview
  • 2.13.2 β Adrenoceptor Agonists Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Impax Laboratories β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 PD-Rx Pharmaceuticals
  • 2.14.1 Business Overview
  • 2.14.2 β Adrenoceptor Agonists Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 PD-Rx Pharmaceuticals β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Athenex Pharmaceutical Division
  • 2.15.1 Business Overview
  • 2.15.2 β Adrenoceptor Agonists Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Athenex Pharmaceutical Division β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 Teva
  • 2.16.1 Business Overview
  • 2.16.2 β Adrenoceptor Agonists Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 Teva β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 Marlex Pharmaceuticals
  • 2.17.1 Business Overview
  • 2.17.2 β Adrenoceptor Agonists Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 Marlex Pharmaceuticals β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 Lannett Company
  • 2.18.1 Business Overview
  • 2.18.2 β Adrenoceptor Agonists Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 Lannett Company β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 West-Ward Pharmaceuticals
  • 2.19.1 Business Overview
  • 2.19.2 β Adrenoceptor Agonists Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 West-Ward Pharmaceuticals β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 United Biomedical
  • 2.20.1 Business Overview
  • 2.20.2 β Adrenoceptor Agonists Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 United Biomedical β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Merck
  • 2.21.1 Business Overview
  • 2.2.2 β Adrenoceptor Agonists Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Merck β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Mylan
  • 2.22.1 Business Overview
  • 2.22.2 β Adrenoceptor Agonists Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Mylan β Adrenoceptor Agonists Revenue, Gross Margin and Market Share (2017-2018)

3 Global β Adrenoceptor Agonists Market Competition, by Players

• 3.1 Global β Adrenoceptor Agonists Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 β Adrenoceptor Agonists Players Market Share
  • 3.2.2 Top 10 β Adrenoceptor Agonists Players Market Share
• 3.3 Market Competition Trend

4 Global β Adrenoceptor Agonists Market Size by Regions

• 4.1 Global β Adrenoceptor Agonists Revenue and Market Share by Regions
• 4.2 North America β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 4.3 Europe β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 4.5 South America β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

5 North America β Adrenoceptor Agonists Revenue by Countries

• 5.1 North America β Adrenoceptor Agonists Revenue by Countries (2014-2019)
• 5.2 USA β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 5.3 Canada β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 5.4 Mexico β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

6 Europe β Adrenoceptor Agonists Revenue by Countries

• 6.1 Europe β Adrenoceptor Agonists Revenue by Countries (2014-2019)
• 6.2 Germany β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 6.3 UK β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 6.4 France β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 6.5 Russia β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 6.6 Italy β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

7 Asia-Pacific β Adrenoceptor Agonists Revenue by Countries

• 7.1 Asia-Pacific β Adrenoceptor Agonists Revenue by Countries (2014-2019)
• 7.2 China β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 7.3 Japan β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 7.4 Korea β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 7.5 India β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

8 South America β Adrenoceptor Agonists Revenue by Countries

• 8.1 South America β Adrenoceptor Agonists Revenue by Countries (2014-2019)
• 8.2 Brazil β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 8.3 Argentina β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 8.4 Colombia β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue β Adrenoceptor Agonists by Countries

• 9.1 Middle East and Africa β Adrenoceptor Agonists Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 9.3 UAE β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 9.4 Egypt β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)
• 9.6 South Africa β Adrenoceptor Agonists Revenue and Growth Rate (2014-2019)

10 Global β Adrenoceptor Agonists Market Segment by Type

• 10.1 Global β Adrenoceptor Agonists Revenue and Market Share by Type (2014-2019)
• 10.2 Global β Adrenoceptor Agonists Market Forecast by Type (2019-2024)
• 10.3 Isoprenaline Revenue Growth Rate (2014-2024)
• 10.4 Dobutamine Revenue Growth Rate (2014-2024)
• 10.5 Salbutamol Revenue Growth Rate (2014-2024)
• 10.6 Terbutaline Revenue Growth Rate (2014-2024)
• 10.7 Salmeterol Revenue Growth Rate (2014-2024)
• 10.8 Formoterol Revenue Growth Rate (2014-2024)
• 10.9 Pirbuterol Revenue Growth Rate (2014-2024)

11 Global β Adrenoceptor Agonists Market Segment by Application

• 11.1 Global β Adrenoceptor Agonists Revenue Market Share by Application (2014-2019)
• 11.2 β Adrenoceptor Agonists Market Forecast by Application (2019-2024)
• 11.3 Chronic Heart Failure Revenue Growth (2014-2019)
• 11.4 Myocardial Infarction Revenue Growth (2014-2019)
• 11.5 Postoperative Hypotension Revenue Growth (2014-2019)
• 11.6 Bronchial Asthma Revenue Growth (2014-2019)
• 11.7 Asthmatic Bronchitis Revenue Growth (2014-2019)
• 11.8 Emphysema Revenue Growth (2014-2019)
• 11.9 Others Revenue Growth (2014-2019)

12 Global β Adrenoceptor Agonists Market Size Forecast (2019-2024)

• 12.1 Global β Adrenoceptor Agonists Market Size Forecast (2019-2024)
• 12.2 Global β Adrenoceptor Agonists Market Forecast by Regions (2019-2024)
• 12.3 North America β Adrenoceptor Agonists Revenue Market Forecast (2019-2024)
• 12.4 Europe β Adrenoceptor Agonists Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific β Adrenoceptor Agonists Revenue Market Forecast (2019-2024)
• 12.6 South America β Adrenoceptor Agonists Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa β Adrenoceptor Agonists Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology